Ravi Shankar Prasad Singh
Pfizer (United States)(US)PRX Research
Publications by Year
Research Areas
Antibiotics Pharmacokinetics and Efficacy, SARS-CoV-2 and COVID-19 Research, Inflammatory Bowel Disease, Antibiotic Resistance in Bacteria, Computational Drug Discovery Methods
Most-Cited Works
- → An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19(2021)1,854 cited
- Comparison of various international guidelines for analytical method validation.(2007)
- → Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir(2022)153 cited
- → Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans(2022)113 cited
- → Why airborne transmission hasn't been conclusive in case of COVID-19? An atmospheric science perspective(2021)61 cited
- → Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects(2019)61 cited
- → Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study(2022)52 cited
- → A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir(2024)49 cited
- → Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis(2015)35 cited
- → Nonlinear Protein Binding: Not What You Think(2018)33 cited